Citigroup’s SpringWorks Therapeutics SWTX Stock Holding History

Citigroup’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-10,000	Closed	-$564K	–	6648
2022 Q1	$564K	Buy	+10,000	New	+$572K	﹤0.01%	3427

Other funds holding SWTX

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Citigroup's SWTX Position: Q3 2025 in Review

Citigroup sold out of SpringWorks Therapeutics (SWTX) in Q3 2025, closing a stake of 1,591,334 shares — an estimated $74.8M sold.

Citigroup first reported a position in SWTX in Q4 2019 and held it in 23 quarters. The position peaked at $74.8M in Q2 2025. 3 funds tracked by Wall St. Rank hold SWTX as of Q3 2025.

Citigroup reported no remaining SpringWorks Therapeutics position as of Q3 2025 after selling out during the quarter.
Citigroup sold 1,591,334 SpringWorks Therapeutics shares in Q3 2025, an estimated $74.8M.
Citigroup first reported a position in SpringWorks Therapeutics in Q4 2019 and held it in 23 quarters.
Citigroup's SpringWorks Therapeutics position peaked at $74.8M in Q2 2025.
3 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2025.

Based on Citigroup's 13F filing for Q3 2025, filed 10 Nov 2025.